Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium - Concepedia

Concepedia

Publication | Open Access

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

DOI Full Paper Access

752

Citations

15

References

2020

Year

Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi, Yi Lin, Saurabh Dahiya, Matthew A. Lunning, Lazaros J. Lekakis, Patrick M. Reagan,

Journal of Clinical Oncology

Abstract

The safety and efficacy of axi-cel in the SOC setting in patients with relapsed/refractory LBCL was comparable to the registrational ZUMA-1 trial.

References

	Year	Citations

Page 1